These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 37729908)
1. Alzheimer's disease: From immunotherapy to immunoprevention. Jucker M; Walker LC Cell; 2023 Sep; 186(20):4260-4270. PubMed ID: 37729908 [TBL] [Abstract][Full Text] [Related]
2. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers? Piazza F; Winblad B J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492 [TBL] [Abstract][Full Text] [Related]
3. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Nitsch RM; Hock C Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Alzheimer's disease. Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646 [TBL] [Abstract][Full Text] [Related]
5. Effect of Lecanemab in Early Alzheimer's Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective. Volloch V; Rits-Volloch S J Alzheimers Dis; 2023; 93(4):1277-1284. PubMed ID: 37212119 [TBL] [Abstract][Full Text] [Related]
6. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511 [TBL] [Abstract][Full Text] [Related]
8. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. Villain N; Planche V; Levy R Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326 [TBL] [Abstract][Full Text] [Related]
11. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease. Wang D; Kowalewski EK; Koch G Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578 [TBL] [Abstract][Full Text] [Related]
12. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease? Panza F; Lozupone M; Dibello V; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP Immunotherapy; 2019 Jan; 11(1):3-6. PubMed ID: 30702009 [No Abstract] [Full Text] [Related]
13. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy. Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992 [TBL] [Abstract][Full Text] [Related]
14. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Blennow K; Hampel H; Zetterberg H Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530 [TBL] [Abstract][Full Text] [Related]
15. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease. Withington CG; Turner RS Front Neurol; 2022; 13():862369. PubMed ID: 35401412 [TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446 [TBL] [Abstract][Full Text] [Related]
17. Still grasping at straws: donanemab in Alzheimer's disease. Doggrell SA Expert Opin Investig Drugs; 2021 Aug; 30(8):797-801. PubMed ID: 34162295 [TBL] [Abstract][Full Text] [Related]
18. Lessons from antiamyloid-β immunotherapies in Alzheimer's disease. Plascencia-Villa G; Perry G Handb Clin Neurol; 2023; 193():267-292. PubMed ID: 36803816 [TBL] [Abstract][Full Text] [Related]
19. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. Tolar M; Hey J; Power A; Abushakra S Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198582 [TBL] [Abstract][Full Text] [Related]
20. Tau immunotherapy for Alzheimer's disease. Pedersen JT; Sigurdsson EM Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]